Semaglutide for Helping Opioid Recovery

NCT06639464 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help reduce cravings for opioids in adults with opioid use disorder.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 46 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-06 · est. completion 2026-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06639464 ↗

Description as written by the study sponsor.

The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD. The secondary aim is to assess the preliminary efficacy, safety, and tolerability of semaglutide for OUD.

Treatments tested

Semaglutide also known as Ozempic Drug

This intervention will consist of the FDA-approved dosing schedule, with terminal dosage based on manufacturer's recommendation to titrate to 1mg over 12 weeks. Participants will receive 0.25mg for the first 4 weeks, 0.5mg for the next 4 weeks, and 1.0mg for the final 4 weeks. IDS will extract semaglutide an draw the doses into syringes for matching placebo doses to also be produced and maintain blind.
Placebo Other

Placebo syringes of saline and matching volume will be produced by IDS.

Main thing measured	Cue-induced Cravings for Opioids
Sponsor	Brigham and Women's Hospital
Conditions studied	Opioid Use Disorder
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06639464 ↗